ResMed (RMD) PT Lowered to $290 at KeyBanc
KeyBanc analyst Brett Fishbin lowered the price target on ResMed (NYSE: RMD) to $290.00 (from $302.00) while maintaining a Overweight rating.
KeyBanc analyst Brett Fishbin lowered the price target on ResMed (NYSE: RMD) to $290.00 (from $302.00) while maintaining a Overweight rating.